Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2019
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Bipolar Disorder (Manic Depression), Pain, Parkinson's Disease, Smoking Addiction, Traumatic Brain Injury, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Cough, Cognitive Disorders, Cognitive Impairment, Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Neuropathic Pain (Neuralgia), Obesity, Panic Disorders and Post-Traumatic Stress Disorder (PTSD).
The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2019, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Reasons to buy
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook